Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

Am J Hematol. 2022 Jan 1;97(1):E7-E10. doi: 10.1002/ajh.26381. Epub 2021 Oct 29.

¹ Department of Pharmacy, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
³ Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
⁴ Department of Medicine, Leukemia Service, Roswell Park Cancer Center, Buffalo, New York, USA.
⁵ Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

No abstract available

Publication types